Last update 21 Nov 2024

XYF19 CAR-T cell therapy (Xi'An Yufan Biotechnology)

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
CRISPR (HPK1) edited CD19specific CART cell therapyXiAn Yufan Biotechnology
+ [1]
Target
CD19 x HPK1
Mechanism
CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), HPK1 inhibitors(Mitogen-activated protein kinase kinase kinase kinase 1 inhibitors)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases
Active Indication
CD19 Expressing MalignanciesRefractory acute lymphoid leukemia
Inactive Indication-
Originator Organization
Xi'an Yufan Biotechnologies Co., Ltd.Xi'an Yufan Biotechnologies Co., Ltd.Startup
Active Organization
Xi'an Yufan Biotechnologies Co., Ltd.Xi'an Yufan Biotechnologies Co., Ltd.Startup
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with XYF19 CAR-T cell therapy (Xi'An Yufan Biotechnology)
NCT04037566 / RecruitingPhase 1IIT
A Safety Study of Autologous T Cells Engineered to Target CD19 and CRISPR Gene Edited to Eliminate Endogenous HPK1 (XYF19 CAR-T Cells) for Relapsed or Refractory Haematopoietic Malignancies.
100 Clinical Results associated with XYF19 CAR-T cell therapy (Xi'An Yufan Biotechnology)
Login to view more data
100 Translational Medicine associated with XYF19 CAR-T cell therapy (Xi'An Yufan Biotechnology)
Login to view more data
100 Patents (Medical) associated with XYF19 CAR-T cell therapy (Xi'An Yufan Biotechnology)
Login to view more data
100 Deals associated with XYF19 CAR-T cell therapy (Xi'An Yufan Biotechnology)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
CD19 Expressing MalignanciesPhase 1
CN
Xi'an Yufan Biotechnologies Co., Ltd.Xi'an Yufan Biotechnologies Co., Ltd.Startup
01 Aug 2019
Refractory acute lymphoid leukemiaPhase 1
CN
Xi'an Yufan Biotechnologies Co., Ltd.Xi'an Yufan Biotechnologies Co., Ltd.Startup
01 Aug 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT04037566 (ASCO2022)
ManualManual
Phase 1
Refractory B Acute Lymphoblastic Leukemia
11
(gcpnyiexhf) = etndoqqmqt xrszcpszth (vimqhqzwch )
View more
Positive
02 Jun 2022
Tecartus
(gcpnyiexhf) = xzaenlmwpi xrszcpszth (vimqhqzwch )
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free